Giovanni Randon
About
Giovanni Randon is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine.
According to data from OpenAlex, Giovanni Randon has authored 51 papers receiving a total of 915 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Giovanni Randon's work include Colorectal Cancer Treatments and Studies (20 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Genetic factors in colorectal cancer (10 papers). Giovanni Randon is often cited by papers focused on Colorectal Cancer Treatments and Studies (20 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Genetic factors in colorectal cancer (10 papers). Giovanni Randon collaborates with scholars based in Italy, United States and Spain. Giovanni Randon's co-authors include Filippo de Braud, Filippo Pietrantonio, Michele Prisciandaro, Michele Del Vecchio, Lorenza Di Guardo, Carolina Cimminiello, Alice Indini, Maria Di Bartolomeo, Joseph Chao and Andrea Luciani and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and British Journal of Cancer.
In The Last Decade
Giovanni Randon
47 papers receiving 909 citations
Peers
Giovanni Randon
Michele Prisciandaro Italy
J. Feng China
Marine Jary France
Myung Hee Chang South Korea
Masako Asayama Japan
Takashi Ichimura Japan
Heike Loeser Germany
Yu-Hong Li China
Alfredo Mellano Italy
Vaia Florou United States
Citations per year, relative to Giovanni Randon Giovanni Randon (= 1×)
peers
Michele Prisciandaro
Countries citing papers authored by Giovanni Randon
Since
Specialization
Citations
This map shows the geographic impact of Giovanni Randon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Randon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Randon more than expected).
Fields of papers citing papers by Giovanni Randon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Giovanni Randon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Randon. The network helps show where Giovanni Randon may publish in the future.
Co-authorship network of co-authors of Giovanni Randon
This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Randon. A scholar is included among the top collaborators of Giovanni Randon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Randon. Giovanni Randon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sabella, Giovanna, et al.. (2025). First-line maintenance strategies and later-line options in patients with advanced gastroesophageal adenocarcinoma. Therapeutic Advances in Medical Oncology. 17. 22834477–22834477.
2.
Ballhausen, Alexej, Federica Morano, Arndt Stahler, et al.. (2025). Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials. British Journal of Cancer. 133(9). 1297–1306.
3.
Bodalal, Zuhir, Eun Kyoung Hong, Stefano Trebeschi, et al.. (2024). Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study. European Radiology Experimental. 8(1). 98–98.
4.
Pietrantonio, Filippo, Giovanni Randon, Sara Lonardi, et al.. (2024). Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial.. Journal of Clinical Oncology. 42(17_suppl). LBA4002–LBA4002.
5.
Conca, Veronica, Paola Vignali, Daniele Rossini, et al.. (2024). Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial.. Journal of Clinical Oncology. 42(16_suppl). 3572–3572.
6.
Conca, Veronica, Roberto Moretto, Carlotta Antoniotti, et al.. (2024). Trifluridine/tipiracil plus capecitabine and bevacizumab as upfront treatment for metastatic colorectal cancer: Results of the phase 1 TriComB study.. Journal of Clinical Oncology. 42(16_suppl). 3558–3558.
7.
Raimondi, Alessandra, Federico Nichetti, Arndt Stahler, et al.. (2023). Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials. European Journal of Cancer. 190. 112945–112945.
8.
Moretto, Roberto, Marco Maria Germani, Javier Ros, et al.. (2023). Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy. JCO Precision Oncology. 7(7). e2300255–e2300255.
9.
Manca, Paolo, Francesca Corti, Rossana Intini, et al.. (2023). Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. European Journal of Cancer. 187. 15–24.
10.
Toma, Alessandro De, Giuseppe Lo Russo, Diego Signorelli, et al.. (2021). Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake. Critical Reviews in Oncology/Hematology. 160. 103299–103299.
11.
Randon, Giovanni, Rossana Intini, Chiara Cremolini, et al.. (2021). Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. European Journal of Cancer. 161. 90–98.
12.
Raimondi, Alessandra, Pierangela Sepe, Mélanie Claps, et al.. (2020). Safety and activity of radium-223 in metastatic castration-resistant prostate cancer: the experience of Istituto Nazionale dei Tumori. Tumori Journal. 106(5). 406–412.
13.
Rutkowski, Piotr, Alice Indini, Barbara Merelli, et al.. (2020). Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Journal for ImmunoTherapy of Cancer. 8(2). e001117–e001117.
14.
Nichetti, Federico, Antonio Marra, Carlo Alberto Giorgi, et al.. (2020). 337P Efficacy of everolimus plus exemestane in CDK 4/6 inhibitors-pretreated or naïve HR-positive/HER2-negative breast cancer patients: A secondary analysis of the EVERMET study. Annals of Oncology. 31. S382–S382.
15.
Schirripa, Marta, Floriana Nappo, Chiara Cremolini, et al.. (2020). KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. Clinical Colorectal Cancer. 19(3). 219–225.
16.
Randon, Giovanni, Giulia Galli, Alessandro De Toma, et al.. (2019). P1.01-135 Salvage Chemotherapy After Immunotherapy Failure in Non-Small-Cell Lung Cancer Patients. Journal of Thoracic Oncology. 14(10). S416–S416.
17.
Galli, Giulia, Alessandro De Toma, Filippo Pagani, et al.. (2019). Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer. 137. 38–42.
18.
Indini, Alice, Lorenza Di Guardo, Carolina Cimminiello, et al.. (2018). Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. Journal of Cancer Research and Clinical Oncology. 145(2). 511–521.
19.
Nicoletto, Maria Ornella, Alessandra Baldoni, Eliana Rulli, et al.. (2016). Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy. Anticancer Research. 36(12). 6541–6546.
20.
Indraccolo, Stefano, Giovanni Randon, Elisabetta Zulato, et al.. (2015). Metformin: a modulator of bevacizumab activity in cancer? A case report. Cancer Biology & Therapy. 16(2). 210–214.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Michele Prisciandaro Breakdown of academic impact, for papers by J. Feng Breakdown of academic impact, for papers by Marine Jary Breakdown of academic impact, for papers by Myung Hee Chang Breakdown of academic impact, for papers by Masako Asayama Breakdown of academic impact, for papers by Takashi Ichimura Breakdown of academic impact, for papers by Heike Loeser Breakdown of academic impact, for papers by Yu-Hong Li Breakdown of academic impact, for papers by Alfredo Mellano Breakdown of academic impact, for papers by Vaia Florou